Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis

On November 9, 2020

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Boeing, NASA Complete First Starliner Space Station Flight Test

Northrop Grumman Australia Announces Tech Showcase Winners

IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022